Xencor, Inc Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
Xencor, Inc (XNCR) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $708.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2017-03-01.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2017-03-01
- Xencor, Inc effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2015 was $708.00K, a 62.76% increase from fiscal 2014.
- Xencor, Inc effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2014 was $435.00K.
- Xencor, Inc effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2012 was $336.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2015-12-31 | $708.00K 10-K · filed 2017-03-01 |
| 2014-12-31 | $435.00K 10-K · filed 2017-03-01 |
| 2012-12-31 | $336.00K 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |